Headlands Technologies LLC Buys 76,536 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Key Points

• Headlands Technologies LLC increased its ownership in Recursion Pharmaceuticals by 85.7%, acquiring an additional 76,536 shares in the first quarter, bringing its total to 165,850 shares valued at approximately $877,000.
• Recursion Pharmaceuticals reported a negative EPS of ($0.41) for the latest quarter, missing expectations, even as the company saw a 33.3% increase in revenue year-over-year to $19.1 million.
• Wall Street analysts have a consensus rating of "Hold" for Recursion Pharmaceuticals, with target prices ranging from $5.00 to $8.00, indicating cautious optimism about its financial outlook.

Headlands Technologies LLC raised its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 85.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 165,850 shares of the company's stock after purchasing an additional 76,536 shares during the period. Headlands Technologies LLC's holdings in Recursion Pharmaceuticals were worth $877,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Man Group plc acquired a new stake in Recursion Pharmaceuticals during the fourth quarter worth $479,000. Rockefeller Capital Management L.P. raised its holdings in shares of Recursion Pharmaceuticals by 323.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 281,922 shares of the company's stock valued at $1,906,000 after buying an additional 215,283 shares during the last quarter. Invesco Ltd. raised its holdings in Recursion Pharmaceuticals by 54.6% during the 4th quarter. Invesco Ltd. now owns 178,619 shares of the company's stock worth $1,207,000 after purchasing an additional 63,068 shares during the last quarter. California State Teachers Retirement System raised its holdings in Recursion Pharmaceuticals by 30.7% during the 4th quarter. California State Teachers Retirement System now owns 231,535 shares of the company's stock worth $1,565,000 after purchasing an additional 54,449 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Recursion Pharmaceuticals by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 863,224 shares of the company's stock worth $4,566,000 after purchasing an additional 12,588 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on RXRX shares. Morgan Stanley started coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 target price for the company. Needham & Company LLC restated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $7.00.

Recursion Pharmaceuticals Price Performance

Shares of RXRX traded down $0.05 during trading hours on Friday, hitting $5.36. 11,988,952 shares of the company were exchanged, compared to its average volume of 29,196,614. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -3.01 and a beta of 0.93. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The company has a quick ratio of 4.11, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The firm's fifty day moving average is $5.40 and its 200 day moving average is $5.89.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The business's quarterly revenue was up 33.3% compared to the same quarter last year. During the same period last year, the business earned ($0.40) earnings per share. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.